Mantle Cell Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 48 expanded access programs, clinical trials, and compassionate use pathways listed for Mantle Cell Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with mantle cell lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 19 programs are currently active or recruiting, with the remaining 29 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, City of Hope Medical Center, BeiGene, ECOG-ACRIN Cancer Research Group, Fred Hutchinson Cancer Center, and others.
By recruiting status
Snapshot of where every Mantle Cell Lymphoma program currently sits in its lifecycle.
- Active / Recruiting19
- Inactive29
Top sponsors
Organisations running the most Mantle Cell Lymphoma programs in the directory.
- M.D. Anderson Cancer Center8 programs
- City of Hope Medical Center5 programs
- BeiGene4 programs
- ECOG-ACRIN Cancer Research Group2 programs
- Fred Hutchinson Cancer Center2 programs
- Masonic Cancer Center, University of Minnesota2 programs
- Academic and Community Cancer Research United1 program
- Alliance for Clinical Trials in Oncology1 program
- Alliance Foundation Trials, LLC.1 program
- Alvaro Alencar, MD1 program
Mantle Cell Lymphoma programs (48)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Comparing Three Chemotherapy Treatments for Newly Diagnosed Mantle Cell Lymphoma — ECOG-ACRIN Cancer Research Group
- Long-term Study of Ibrutinib for Ongoing Access and Safety Monitoring — Janssen Research & Development, LLC
- Study on AZD0486 Alone or with Other Cancer Drugs for Treating Mature B-Cell Blood Cancers — AstraZeneca
- Study on Nemtabrutinib for Patients with Difficult-to-Treat Blood Cancers — ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Study on Sonrotoclax and Zanubrutinib for Treating Adults with Relapsed or Hard-to-Treat Mantle Cell Lymphoma — BeiGene
- Study on Acalabrutinib and Rituximab for Treating Untreated Mantle Cell Lymphoma — M.D. Anderson Cancer Center
- Study on Acalabrutinib, Lenalidomide, and Rituximab for Patients with Untreated Mantle Cell Lymphoma — Weill Medical College of Cornell University
- Study on Acalabrutinib, Umbralisib, and Ublituximab for Treating Untreated Mantle Cell Lymphoma — City of Hope Medical Center
- BRAZAN Trial for Initial Treatment of Mantle Cell Lymphoma (MCL) — Christine Ryan
- GATE1: Study on Pirtobrutinib, Rituximab, and Venetoclax for Untreated Mantle Cell Lymphoma — M.D. Anderson Cancer Center
- Study on Ibrutinib and Rituximab for Treating Mantle Cell Lymphoma — M.D. Anderson Cancer Center
- Study on Ibrutinib, Rituximab, Venetoclax, and Chemotherapy for Newly Diagnosed Mantle Cell Lymphoma — M.D. Anderson Cancer Center
- Study on Nemtabrutinib and Rituximab for Treating Mantle Cell Lymphoma — City of Hope Medical Center
- Phase II Study of Palbociclib and Ibrutinib for Treating Mantle Cell Lymphoma — Alliance Foundation Trials, LLC.
- Study on Rituximab/Bendamustine and Rituximab/Cytarabine for Treating Mantle Cell Lymphoma — Dana-Farber Cancer Institute
- Study on Sonrotoclax, Rituximab, and Zanubrutinib for Treating Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma — Fred Hutchinson Cancer Center
- Home-Based Cancer Treatment Program for Patients in the Florida Panhandle and Nearby Areas — Mayo Clinic
- Study on MGTA-456 for Patients with High-Risk Cancer — Masonic Cancer Center, University of Minnesota
- Study on Venetoclax, Lenalidomide, and Rituximab for Untreated Mantle Cell Lymphoma — City of Hope Medical Center
- Study on BGB-16673 for Patients with B-Cell Blood Cancers — BeiGene
- Study on the Safety and Effectiveness of CTX112 for Treating Difficult or Returning B-Cell Cancers — CRISPR Therapeutics AG
- Study on Zilovertamab Vedotin as a Single Treatment and in Combination for Aggressive and Slow-Growing B-cell Blood Cancers — Merck Sharp & Dohme LLC
- Study on Acalabrutinib and Obinutuzumab for Treating Untreated Follicular Lymphoma or Other Slow-Growing Non-Hodgkin Lymphomas — Emory University
- Acalabrutinib for Treating Patients with Mantle Cell Lymphoma Who Cannot Tolerate Ibrutinib — M.D. Anderson Cancer Center
- Study on Acalabrutinib, Obinutuzumab, and Glofitamab for Treating Relapsed or Hard-to-Treat Mantle Cell Lymphoma — City of Hope Medical Center
- Study on Stem Cell Transplant Followed by Polatuzumab Vedotin for B-cell Non-Hodgkin and Hodgkin Lymphoma — New York Medical College
- Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Relapsed/Refractory and Untreated Mantle Cell Lymphoma — Austin I Kim
- Study on Cytokine-Treated Veto Cells for Patients with Blood Cancers After Stem Cell Transplant — M.D. Anderson Cancer Center
- Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for Treating Blood Cancers — Fred Hutchinson Cancer Center
- Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel — Kite, A Gilead Company
- Study on Glofitamab, Ibrutinib, and Obinutuzumab for Treating Mantle Cell Lymphoma — OHSU Knight Cancer Institute
- Study on Glofitamab with Obinutuzumab, Venetoclax, and Lenalidomide for Treating Newly Diagnosed High Risk Mantle Cell Lymphoma — City of Hope Medical Center
- Study on Glofitamab and Pirtobrutinib for Treating Relapsed or Resistant Mantle Cell Lymphoma — C. Babis Andreadis
- Local Production of CAR T-Cell Therapy for Treating B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia — John Lister
- Study on Modified VR-CAP and Acalabrutinib as First Treatment for Transplant-Eligible Patients with Mantle Cell Lymphoma — Academic and Community Cancer Research United
- Study on Myeloablative Stem Cell Transplant with Donor for Blood Disorders — Masonic Cancer Center, University of Minnesota
- Phase 2 Study of Pirtobrutinib and Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma — H. Lee Moffitt Cancer Center and Research Institute
- Phase II Study of Pirtobrutinib and Venetoclax for Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL) — M.D. Anderson Cancer Center
- Phase II Study of Pirtobrutinib and Rituximab in Untreated Low and Intermediate Risk Mantle Cell Lymphoma Patients — M.D. Anderson Cancer Center
- Phase II Study of Venetoclax and Rituximab as First Treatment in Older Adults with Mantle Cell Lymphoma — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study on Rituximab With or Without Stem Cell Transplant for Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission — ECOG-ACRIN Cancer Research Group
- Study on BGB-11417 for Treating Relapsed or Hard-to-Treat Mantle Cell Lymphoma — BeiGene
- Study of Iopofosine I 131 (CLR 131) for Certain B-Cell Blood Cancers and Waldenstrom Macroglobulinemia — Cellectar Biosciences, Inc.
- Study on the Safety and Early Effectiveness of Ibrutinib and Pembrolizumab in Patients with Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) — Joshua Brody
- Testing Continuous Versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma — Alliance for Clinical Trials in Oncology
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation — University of Michigan Rogel Cancer Center
- Study on Zanubrutinib for Patients with B-Cell Lymphoma Who Cannot Tolerate Previous BTK Inhibitor Treatments — BeiGene
- Study on Zanubrutinib and Tafasitamab for Mantle Cell Lymphoma — Alvaro Alencar, MD
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Mantle Cell Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.